In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

NeurogesX, Inc.

Latest From NeurogesX, Inc.

Finance Watch: CureVac’s IPO Is Ready For Launch

Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m. 

Financing Business Strategies

Deals Shaping the Medical Industry, January 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.

Deals BioPharmaceutical

Launch Or License: Taking Your First Drug To Europe

Directly launching a drug in Europe is the most difficult path for US-based biopharma companies, many of which decide to out-license rights for that territory. But, for the right asset, it’s also the most rewarding. The authors review 11 years of EMA approvals to examine European entry strategies’ effects on company valuations.

BioPharmaceutical Europe

Acorda pays $8m for NeurogesX pain assets

Acorda Therapeutics paid NeurogesX $7.9 million up front for a commercial pain therapy and a late-stage, topical pain drug candidate – from which Acorda expects to derive the most value – as NeurogesX prepares to settle its debts and wind down its operations.

Metabolic Disorders Infectious Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
      • Transdermal
UsernamePublicRestriction

Register